Why the study?
Whether good glycemic control yields clinical benefits in diabetic patients with chronic total occlusion remained a matter of debate.
Does good glycemic control (HbA1c < 7.0) reduce major adverse cardiovascular events in diabetic patients with chronic total occlusion?
Does good glycemic control (HbA1c < 7.0) reduce major adverse cardiovascular events in diabetic patients with chronic total occlusion?
Good glycemic control (HbA1c < 7.0) is associated with improved clinical prognosis and reduced MACE in diabetic patients with chronic total occlusion, particularly those with unsuccessful revascularization.
Answers are grounded in this paper and cite their sources.
May support glycemic targets in diabetic CTO patients; hypothesis-generating for MACE reduction, pending RCTs.
BACKGROUND: Whether good glycemic control can result in clinical benefits for diabetic chronic total occlusion (CTO) patients is still a matter of debate. METHODS: = 581). We further subdivided the patients into the successful CTO revascularization (CTO-SR) and nonsuccessful CTO revascularization (CTO-NSR) groups. Kaplan-Meier analysis and Cox regression before and after propensity score matching were used to compare major adverse cardiovascular events (MACE) and other endpoints. CONCLUSIONS: HbA1c < 7.0 was associated with a reduced incidence of MACE, which was mainly attributed to a reduction in repeat revascularization. Good glycemic control can improve diabetic CTO patients' clinical prognosis, especially in CTO-NSR patients.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: